The future of cell and gene therapy (CGT) is rapidly shifting—from complex, costly ex vivo procedures to streamlined, scalable in vivo solutions. This webinar will explore how microfluidics technology is catalyzing this transformation, and how the integration of platforms like Cyto-Mine® is building the next generation of in vivo-ready therapeutics.
In traditional ex vivo cell therapies, patient cells must be harvested, engineered, expanded and reinfused—a process that is labour-intensive, time-consuming and difficult to scale. In contrast, in vivo therapy directly delivers gene editing tools or reprogramming vectors into the patient bypassing the need for cell manipulation outside the body.
In this webinar, the expert speaker will focus on a first-in-human clinical trial for treating tumors with NF2 mutations. They will discuss how microfluidics has been leveraged to develop a stable producer cell line for manufacturing therapeutic-grade vectors. These vectors can be used in in vivo gene therapy and in vivo CAR-T applications. Using Cyto-Mine®’s single-cell resolution, high-throughput screening and intelligent clone selection, scalable manufacturing platforms can be built. These platforms ensure the precision and consistency required for in vivo therapeutics.
This webinar will outline how microfluidics is not only optimizing vector production but also reshaping the entire therapeutic model—paving the way for faster, safer and more accessible treatments.
Register for this webinar today to discover how microfluidics is revolutionizing cell and gene therapy shifting from complex, costly procedures to more streamlined, in vivo solutions.
Speaker
Dr. Luke Zhou, CEO, Santo Therapeutics
Dr. Luke Zhou is the Founder and CEO of Santo Therapeutics Ltd. He earned his PhD in Biochemistry from Heriot-Watt University, Edinburgh, and has over a decade of experience in cancer research and gene therapy.
Dr. Zhou’s academic contributions have been featured in Oncogene (Nature Publishing Group), with co-authored research published in Cell and Cancer Cell. His work has earned recognition and awards from Forbes China, Cancer Research UK and The Children’s Brain Tumor Foundation (US).
Beyond his scientific achievements, Dr. Zhou served as Executive President of the Confederation of Chinese Business UK (CCBUK) and is committed to strengthening collaborations between the UK and China in the Life Sciences and Healthcare sectors.
Message PresenterWho Should Attend?
This webinar will appeal to:
- C-Suite Executives
- Those working in pharma/biotech
- Lab Managers
- Principal Investigators/Senior Scientists
- Those involved in the development of cell and gene therapies
What You Will Learn
Attendees will learn about:
- Why the field is moving from ex vivo to in vivo gene and cell therapies—and what this shift means for scalability and accessibility
- How microfluidics platforms like Cyto-Mine® are central to enabling in vivo therapies from vector development to stable cell line screening
- What the future holds for decentralized, patient-friendly and high-impact gene therapy delivery
- How next-generation multiplexed microfluidic technologies are redefining cell-based assays
Xtalks Partner
Sphere Bio
Sphere Bio develops and manufactures single-cell analysis and monoclonality assurance systems to enable researchers to find, analyze and isolate the most valuable cells, with ease and speed.
Sphere Bio’s proprietary picodroplet microfluidic platforms are designed specifically for single-cell screening and isolation, allowing users to encapsulate and analyze single cells within a picodroplet, while maintaining viability. Harnessing this technology, the Company’s range of novel microfluidic tools facilitate leading-edge research and accelerate biotherapeutic discovery and development and cell therapy workflows, streamlining the journey of discovery in labs, globally.
Sphere Bio is based at Granta Park in Cambridgeshire (UK). The Company has also internationalized its business via a global network of direct sales and support staff throughout the United States, Europe and experienced distribution channels across APAC.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account